Literature DB >> 7026082

Pulmonary vascular disease with congenital heart lesions: pathologic features and causes.

J I Hoffman, A M Rudolph, M A Heymann.   

Abstract

Pulmonary vascular disease, a serious complication of many congenital heart lesions, has three major components: increased muscularity of small pulmonary arteries; intimal hyperplasia, scarring and thrombosis; and reduced numbers of intraacinar arteries. The muscularity is due to increased stress on the vessel wall, and is reversible. The intimal changes may be due to endothelial damage, causing an imbalance between prostacyclin and thromboxane A2 production and leading to local platelet aggregation. This, in turn, may stimulate migration and division of myointimal cells, which thicken the intima and lead to scarring and thrombosis. Extensive intimal changes are probably irreversible, but the possibility of preventing them by use of agents that inhibit platelet aggregation needs to be considered. The mechanism of a decrease in numbers of intraacinar arteries is unexplained. The potential for growth of new vessels after corrective surgery of the cardiac defect is an important factor in restoring pulmonary vascular resistance to normal. Available evidence suggests that this growth potential is reduced after 2 years of age and argues for early surgical relief of pulmonary vascular stresses.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7026082     DOI: 10.1161/01.cir.64.5.873

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  21 in total

1.  Eisenmenger's Syndrome.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  1999-12

2.  Pulmonary hypertension in patients with complete transposition of the great arteries: midterm results after surgery.

Authors:  Y Nakajima; K Momma; M Seguchi; M Nakazawa; Y Imai
Journal:  Pediatr Cardiol       Date:  1996 Mar-Apr       Impact factor: 1.655

Review 3.  Role of reactive oxygen species in neonatal pulmonary vascular disease.

Authors:  Stephen Wedgwood; Robin H Steinhorn
Journal:  Antioxid Redox Signal       Date:  2014-02-19       Impact factor: 8.401

Review 4.  Pulmonary hypertension in children: perioperative management.

Authors:  F A Burrows; J R Klinck; M Rabinovitch; D J Bohn
Journal:  Can Anaesth Soc J       Date:  1986-09

5.  Shunt Surgery, Right Heart Catheterization, and Vascular Morphometry in a Rat Model for Flow-induced Pulmonary Arterial Hypertension.

Authors:  Diederik E van der Feen; Michel Weij; Annemieke Smit-van Oosten; Lysanne M Jorna; Quint A J Hagdorn; Beatrijs Bartelds; Rolf M F Berger
Journal:  J Vis Exp       Date:  2017-02-11       Impact factor: 1.355

6.  Natural and modified history of complete atrioventricular septal defect--a 17 year study.

Authors:  P Frontera-Izquierdo; G Cabezuelo-Huerta
Journal:  Arch Dis Child       Date:  1990-09       Impact factor: 3.791

7.  Assessment of pulmonary hypertension in the pediatric catheterization laboratory: current insights from the Magic registry.

Authors:  Kevin D Hill; D Scott Lim; Allen D Everett; D Dunbar Ivy; J Donald Moore
Journal:  Catheter Cardiovasc Interv       Date:  2010-11-15       Impact factor: 2.692

8.  Altered Carnitine Homeostasis in Children With Increased Pulmonary Blood Flow Due to Ventricular Septal Defects.

Authors:  Stephen M Black; Aida Field-Ridley; Shruti Sharma; Sanjiv Kumar; Roberta L Keller; Rebecca Kameny; Emin Maltepe; Sanjeev A Datar; Jeffrey R Fineman
Journal:  Pediatr Crit Care Med       Date:  2017-10       Impact factor: 3.624

9.  Levosimendan is superior to dobutamine as an inodilator in the treatment of pulmonary hypertension for children undergoing cardiac surgery.

Authors:  Abdelhay A Ebade; Mohamed A Khalil; Ahmed K Mohamed
Journal:  J Anesth       Date:  2012-12-09       Impact factor: 2.078

10.  Infant pulmonary vascular model based on the pulmonary input impedance spectrum.

Authors:  N F Radke; C L Lucas; B R Wilcox; B A Keagy
Journal:  Ann Biomed Eng       Date:  1985       Impact factor: 3.934

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.